相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of Stealthy Nanomaterials
Riccardo Rampado et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)
Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure
Esther Kuilamu et al.
PHARMACEUTICAL RESEARCH (2020)
Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats
Shadabul Haque et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs
Yaelle Bavli et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Drug formulation and nanomedicine approaches to targeting lymphatic cancer metastases
Lili Wang et al.
NANOMEDICINE (2019)
Peripheral monocyte counts predict the clinical outcome for patients with colorectal cancer: a systematic review and meta-analysis
Shu Wen et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil(A (R)) or Caelyx(A (R)) in advanced ovarian cancer
Shravanti Bhowmik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes
Zahraa S. Al-Ahmady et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
Kurtis M. Host et al.
MBIO (2017)
Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population
Halli Benasutti et al.
BIOCONJUGATE CHEMISTRY (2017)
17β-estradiol modulates the viability, phenotype, endocytosis, and inflammatory cytokine expression of RAW264.7 macrophages
Linsong Yang et al.
EUROPEAN JOURNAL OF INFLAMMATION (2016)
Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier
Kenji Yokoi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Liposome-protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines
Giulio Caracciolo
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)
Tumor-host signaling interaction reveals a systemic, age-dependent splenic immune influence on tumor development
Afshin Beheshti et al.
ONCOTARGET (2015)
Interleukin-1β triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells
Mirjam Schenk et al.
IMMUNOLOGY (2014)
Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents
Ryan F. Schell et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin
Gemma M. Ryan et al.
JOURNAL OF CONTROLLED RELEASE (2013)
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases
Lisa M. Kaminskas et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
Juan Lao et al.
JOURNAL OF DRUG DELIVERY (2013)
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
Ninh M. La-Beck et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A simple procedure for estimation of total body surface area and determination of a new value of Meeh's constant in rats
E. Gouma et al.
LABORATORY ANIMALS (2012)
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems
Lisa M. Kaminskas et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas
Yun Fan et al.
ACTA PHARMACOLOGICA SINICA (2011)
Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats
Gina Song et al.
CANCER RESEARCH (2010)
Estrogen augments the T cell-dependent but not the T-independent immune response
Monika Adori et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers
Lisa M. Kaminskas et al.
MOLECULAR PHARMACEUTICS (2008)
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts
William C. Zamboni et al.
CLINICAL CANCER RESEARCH (2007)
Non-classical actions of testosterone: an update
Faisal Rahman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2007)
Cationic poly-L-lysine dendrimers: Pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats
Ben J. Boyd et al.
MOLECULAR PHARMACEUTICS (2006)
High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells
JW Wright et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate
KV Desai et al.
MOLECULAR ENDOCRINOLOGY (2004)
In vivo modulation of the circulating lymphocyte subsets and monocytes by androgen
GH Yao et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
分享论文
